Obinutuzumab in Kidney Transplantation: Effect on B-cell Counts and Crossmatch Tests

It is with great interest we read the article authored by NasrAllah et al1 suggesting an important characteristic of obinutuzumab compared with rituximab in complement dependent cytotoxicity crossmatch (CDC) testing. Since the implementation of rituximab in desensitization therapy, it was noted that CDC test for B cells could often be strongly positive without evidence of HLA antibodies reactive with B cells. It is important to understand the...